EP
TVRD

Elkfork Partners’s Tvardi Therapeutics TVRD Stock Holding History

Elkfork Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-93
Closed -$41K – 1034
2018
Q1 		$41K Sell
93
-277
-75% -$134K ﹤0.01% 997
2017
Q4 		$163K Sell
370
-220
-37% -$100K ﹤0.01% 836
2017
Q3 		$291K Sell
590
-74
-11% -$37.1K 0.01% 621
2017
Q2 		$368K Sell
664
-221
-25% -$140K 0.01% 558
2017
Q1 		$586K Hold
885
– – 0.02% 417
2016
Q4 		$296K Buy
+885
New +$284K 0.01% 519

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Elkfork Partners's TVRD Position: Q2 2018 in Review

Elkfork Partners sold out of Tvardi Therapeutics (TVRD) in Q2 2018, closing a stake of 93 shares — an estimated $41K sold.

Elkfork Partners first reported a position in TVRD in Q4 2016 and held it in 6 quarters. The position peaked at $586K in Q1 2017. 130 funds tracked by Wall St. Rank hold TVRD as of Q2 2018.

  • Elkfork Partners reported no remaining Tvardi Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Elkfork Partners sold 93 Tvardi Therapeutics shares in Q2 2018, an estimated $41K.
  • Elkfork Partners first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 6 quarters.
  • Elkfork Partners's Tvardi Therapeutics position peaked at $586K in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2018.

Based on Elkfork Partners's 13F filing for Q2 2018, filed 14 Aug 2018.